Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Avanir Pharmaceuticals (AVN) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Avanir Pharmaceuticals. Table 2 shows the detailed insider transactions. This company's CIK number is 858803.
Total stock buying since 2014: $0.
Total stock sales since 2014: $9,586,924.
Total stock option exercises since 2014: $480,850.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2014 | 0 | $0 | 967,073 | $9,586,924 | 257,451 | $480,850 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2014-12 | 0 | $0 | 328,965 | $5,573,979 | 257,451 | $480,850 |
| 2014-11 | 0 | $0 | 15,000 | $225,000 | 0 | $0 |
| 2014-10 | 0 | $0 | 38,073 | $448,177 | 0 | $0 |
| 2014-09 | 0 | $0 | 80,000 | $800,999 | 0 | $0 |
| 2014-08 | 0 | $0 | 11,780 | $63,735 | 0 | $0 |
| 2014-05 | 0 | $0 | 493,255 | $2,475,034 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-12-18 | Siffert Joao Md (SVP, R&D) | Sale | 15,505 | 16.93 | 262,499 |
| 2014-12-18 | Siffert Joao Md (SVP, R&D) | Option Ex | 32,291 | 2.59 | 83,633 |
| 2014-12-18 | Ocampo Christine (Vice President, Finance) | Sale | 5,780 | 16.93 | 97,855 |
| 2014-12-17 | Katkin Keith (President and CEO) | Sale | 62,520 | 16.93 | 1,058,463 |
| 2014-12-16 | Ocampo Christine (Vice President, Finance) | Sale | 30,000 | 16.94 | 508,200 |
| 2014-12-16 | Ocampo Christine (Vice President, Finance) | Option Ex | 30,000 | 3.38 | 101,550 |
| 2014-12-15 | Katkin Keith (President and CEO) | Sale | 215,160 | 16.95 | 3,646,962 |
| 2014-12-15 | Katkin Keith (President and CEO) | Option Ex | 195,160 | 1.51 | 295,667 |
| 2014-11-28 | Palekar Rohan (SVP & Chief Commercial Officer) | Sale | 15,000 | 15.00 | 225,000 |
| 2014-10-24 | Siffert Joao Md (SVP, R&D) | Sale | 8,426 | 11.80 | 99,426 |
| 2014-10-24 | Katkin Keith (President and CEO) | Sale | 27,567 | 11.76 | 324,187 |
| 2014-10-24 | Ocampo Christine (Vice President, Finance) | Sale | 2,080 | 11.81 | 24,564 |
| 2014-09-15 | Palekar Rohan (SVP & Chief Commercial Officer) | Sale | 25,000 | 11.25 | 281,250 |
| 2014-09-15 | Ocampo Christine (Vice President, Finance) | Sale | 55,000 | 9.45 | 519,749 |
| 2014-08-26 | Ocampo Christine (Vice President, Finance) | Sale | 2,110 | 6.10 | 12,871 |
| 2014-08-01 | Katkin Keith (President and CEO) | Sale | 9,670 | 5.26 | 50,864 |
| 2014-05-28 | Siffert Joao Md (SVP, R&D) | Sale | 13,547 | 5.18 | 70,173 |
| 2014-05-28 | Katkin Keith (President and CEO) | Sale | 442,212 | 5.01 | 2,215,482 |
| 2014-05-16 | Ocampo Christine (Vice President, Finance) | Sale | 11,900 | 4.88 | 58,072 |
| 2014-05-14 | Ocampo Christine (Vice President, Finance) | Sale | 25,596 | 5.13 | 131,307 |
Insider trading activities including stock purchases, stock sales, and option exercises of AVN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Avanir Pharmaceuticals (symbol AVN, CIK number 858803) see the Securities and Exchange Commission (SEC) website.